EP Patent

EP2944319A1 — Buffered ophthalmic compositions and use thereof

Assigned to Arava Bio-Tech Ltd · Expires 2015-11-18 · 10y expired

What this patent protects

Use of a PKC-α inhibitor or a physiologically acceptable salt thereof in the preparation of an ophthalmic composition for treating dry eye in a subject.

USPTO Abstract

Use of a PKC-α inhibitor or a physiologically acceptable salt thereof in the preparation of an ophthalmic composition for treating dry eye in a subject.

Drugs covered by this patent

oxymetazoline-hydrochloride (OXYMETAZOLINE HYDROCHLORIDE)

Patent Metadata

Patent number: EP2944319A1
Jurisdiction: EP
Classification: —
Expires: 2015-11-18
Drug substance claim: No
Drug product claim: No
Assignee: Arava Bio-Tech Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.